DarioHealth (Nasdaq:DRIO) announced today that a new analysis demonstrated a significant cost reduction for users of its digital therapeutic platform.
Sanofi U.S. conducted the analysis, which showed lower costs of care for DarioHealth users compared to non-users with type 2 diabetes. The study used matched claims to show an estimated $5,077 in medical cost savings for the DarioHealth users.
Get the full story at our sister site, Drug Delivery Business News.